PT852585E - Metodo de tratamento da doenca de alzheimer utilizando um produto proteico de factor neurotrofico derivado de uma linha de celulas gliais. - Google Patents

Metodo de tratamento da doenca de alzheimer utilizando um produto proteico de factor neurotrofico derivado de uma linha de celulas gliais.

Info

Publication number
PT852585E
PT852585E PT96932325T PT96932325T PT852585E PT 852585 E PT852585 E PT 852585E PT 96932325 T PT96932325 T PT 96932325T PT 96932325 T PT96932325 T PT 96932325T PT 852585 E PT852585 E PT 852585E
Authority
PT
Portugal
Prior art keywords
treating
disease
alzheimer
neurotrophic factor
line
Prior art date
Application number
PT96932325T
Other languages
English (en)
Inventor
Lawrence R Williams
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Inc filed Critical Amgen Inc
Publication of PT852585E publication Critical patent/PT852585E/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/185—Nerve growth factor [NGF]; Brain derived neurotrophic factor [BDNF]; Ciliary neurotrophic factor [CNTF]; Glial derived neurotrophic factor [GDNF]; Neurotrophins, e.g. NT-3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Psychology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
PT96932325T 1995-09-28 1996-09-23 Metodo de tratamento da doenca de alzheimer utilizando um produto proteico de factor neurotrofico derivado de uma linha de celulas gliais. PT852585E (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/535,682 US5731284A (en) 1995-09-28 1995-09-28 Method for treating Alzheimer's disease using glial line-derived neurotrophic factor (GDNF) protein product

Publications (1)

Publication Number Publication Date
PT852585E true PT852585E (pt) 2005-04-29

Family

ID=24135315

Family Applications (1)

Application Number Title Priority Date Filing Date
PT96932325T PT852585E (pt) 1995-09-28 1996-09-23 Metodo de tratamento da doenca de alzheimer utilizando um produto proteico de factor neurotrofico derivado de uma linha de celulas gliais.

Country Status (13)

Country Link
US (1) US5731284A (pt)
EP (1) EP0852585B1 (pt)
JP (1) JP4761409B2 (pt)
AT (1) ATE288447T1 (pt)
AU (1) AU711053B2 (pt)
CA (1) CA2232789C (pt)
DE (1) DE69634301T2 (pt)
DK (1) DK0852585T3 (pt)
ES (1) ES2237775T3 (pt)
NZ (1) NZ319040A (pt)
PT (1) PT852585E (pt)
SI (1) SI0852585T1 (pt)
WO (1) WO1997011965A1 (pt)

Families Citing this family (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6184200B1 (en) * 1995-09-28 2001-02-06 Amgen Inc. Truncated glial cell line-derived neurotrophic factor
US6677135B1 (en) 1996-05-08 2004-01-13 Biogen, Inc. Ret ligand (RetL) for stimulating neutral and renal growth
US6207656B1 (en) * 1997-05-22 2001-03-27 Cephalon, Inc. Vitamin D analogues and their neuronal effects
CA2301693A1 (en) 1997-09-19 1999-04-01 Klaus Unsicker Cytokines having neurotrophic activity
US6761888B1 (en) 2000-05-26 2004-07-13 Neuralab Limited Passive immunization treatment of Alzheimer's disease
US6787523B1 (en) * 1997-12-02 2004-09-07 Neuralab Limited Prevention and treatment of amyloidogenic disease
TWI239847B (en) * 1997-12-02 2005-09-21 Elan Pharm Inc N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease
US7790856B2 (en) * 1998-04-07 2010-09-07 Janssen Alzheimer Immunotherapy Humanized antibodies that recognize beta amyloid peptide
US7588766B1 (en) 2000-05-26 2009-09-15 Elan Pharma International Limited Treatment of amyloidogenic disease
US20080050367A1 (en) * 1998-04-07 2008-02-28 Guriq Basi Humanized antibodies that recognize beta amyloid peptide
US7964192B1 (en) 1997-12-02 2011-06-21 Janssen Alzheimer Immunotherapy Prevention and treatment of amyloidgenic disease
US20050059802A1 (en) * 1998-04-07 2005-03-17 Neuralab Ltd Prevention and treatment of amyloidogenic disease
AU758155B2 (en) 1998-04-29 2003-03-13 Oklahoma Medical Research Foundation Construction of retroviral producer cells from adenoviral and retroviral vectors
AU1822000A (en) * 1998-11-20 2000-06-13 Yale University Effects of gdnf and ngf on sodium channels in drg neurons
DE60137414D1 (de) 2000-05-05 2009-03-05 Univ City Zusammensetzungen zur stimulierung der regeneration und der wiederherstellung des nervensystems durch regulierung der arginase 1- und polyamin-synthese
US6781029B2 (en) 2000-07-13 2004-08-24 University Of South Florida Transgenic animal and methods
US7700751B2 (en) 2000-12-06 2010-04-20 Janssen Alzheimer Immunotherapy Humanized antibodies that recognize β-amyloid peptide
TWI255272B (en) * 2000-12-06 2006-05-21 Guriq Basi Humanized antibodies that recognize beta amyloid peptide
KR20050021026A (ko) * 2001-06-15 2005-03-07 주식회사 장생도라지 장생도라지 추출물을 포함하는 면역계의 이상으로부터발생하는 질병의 예방 및 치료용 약제학적 조성물
US7455666B2 (en) * 2001-07-13 2008-11-25 Board Of Regents, The University Of Texas System Methods and apparatuses for navigating the subarachnoid space
US7150737B2 (en) * 2001-07-13 2006-12-19 Sci/Med Life Systems, Inc. Methods and apparatuses for navigating the subarachnoid space
MY139983A (en) * 2002-03-12 2009-11-30 Janssen Alzheimer Immunotherap Humanized antibodies that recognize beta amyloid peptide
AU2003268484A1 (en) * 2002-09-06 2004-03-29 The General Hospital Corporation Delivery of therapeutics to the brain and spinal cord
RU2390350C2 (ru) * 2003-02-01 2010-05-27 Ньюралаб Лимитед Активная иммунизация для создания антител к растворимому а-бета
US8946151B2 (en) * 2003-02-24 2015-02-03 Northern Bristol N.H.S. Trust Frenchay Hospital Method of treating Parkinson's disease in humans by convection-enhanced infusion of glial cell-line derived neurotrophic factor to the putamen
US20040209810A1 (en) * 2003-02-24 2004-10-21 Gill Steven S. Method of treating Parkinson's disease in humans by intraputaminal infusion of glial cell-line derived neurotrophic factor
TWI374893B (en) * 2003-05-30 2012-10-21 Janssen Alzheimer Immunotherap Humanized antibodies that recognize beta amyloid peptide
US20050225165A1 (en) * 2004-04-13 2005-10-13 Naik Sanjeev M Brake by-wire control system
GB2414934A (en) * 2004-06-11 2005-12-14 Gill Steven Streatfield Treatment of Parkinson's disease with GDNF
EP1838854B1 (en) 2004-12-15 2012-10-31 Janssen Alzheimer Immunotherapy Antibodies that recognize Beta Amyloid Peptide
EP1838349A1 (en) * 2004-12-15 2007-10-03 Neuralab, Ltd. Amyloid beta antibodies for use in improving cognition
EP1838348B1 (en) * 2004-12-15 2013-06-26 Janssen Alzheimer Immunotherapy Humanized amyloid beta antibodies for use in improving cognition
WO2007048413A1 (en) * 2005-10-28 2007-05-03 Nsgene A/S IMPLANTABLE BIOCOMPATIBLE IMMtTNOISOLATORY VEHICLE FOR DELIVERY OF GDNF
WO2007059135A2 (en) * 2005-11-10 2007-05-24 Satoris, Inc. Methods of treating alzheimer's disease
US8784810B2 (en) * 2006-04-18 2014-07-22 Janssen Alzheimer Immunotherapy Treatment of amyloidogenic diseases
WO2007127803A2 (en) 2006-04-25 2007-11-08 The Regents Of The University Of California Administration of growth factors for the treatment of cns disorders
JP2009535360A (ja) * 2006-04-26 2009-10-01 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 高分子量神経治療薬の対流増加送達のための組成物および方法
US8003097B2 (en) * 2007-04-18 2011-08-23 Janssen Alzheimer Immunotherapy Treatment of cerebral amyloid angiopathy
EP2146746A4 (en) * 2007-04-18 2011-03-23 Janssen Alzheimer Immunotherap PREVENTIVE AND TREATING ZEREBRALER AMYLOID ANGIOPATHY
PL2182983T3 (pl) 2007-07-27 2014-10-31 Janssen Alzheimer Immunotherap Leczenie chorób amyloidowych z wykorzystaniem humanizowanych przeciwciał specyficznych względem Abeta
JO3076B1 (ar) * 2007-10-17 2017-03-15 Janssen Alzheimer Immunotherap نظم العلاج المناعي المعتمد على حالة apoe
WO2009128057A2 (en) 2008-04-18 2009-10-22 UNIVERSITY COLLEGE DUBLIN, NATIONAL UNIVERSITY OF IRELAND, DUBLIN et al Psycho-pharmaceuticals
US9067981B1 (en) 2008-10-30 2015-06-30 Janssen Sciences Ireland Uc Hybrid amyloid-beta antibodies
WO2011044387A2 (en) 2009-10-07 2011-04-14 The Board Of Regents Of The University Of Texas System Pressure-sensing medical devices, systems and methods, and methods of forming medical devices
US9067988B2 (en) 2010-12-01 2015-06-30 Alderbio Holdings Llc Methods of preventing or treating pain using anti-NGF antibodies
US11214610B2 (en) 2010-12-01 2022-01-04 H. Lundbeck A/S High-purity production of multi-subunit proteins such as antibodies in transformed microbes such as Pichia pastoris
JP6190723B2 (ja) 2010-12-01 2017-08-30 アルダーバイオ ホールディングス エルエルシー 抗ｎｇｆ組成物およびその使用
US9539324B2 (en) 2010-12-01 2017-01-10 Alderbio Holdings, Llc Methods of preventing inflammation and treating pain using anti-NGF compositions
US9078878B2 (en) 2010-12-01 2015-07-14 Alderbio Holdings Llc Anti-NGF antibodies that selectively inhibit the association of NGF with TrkA, without affecting the association of NGF with p75
US9884909B2 (en) 2010-12-01 2018-02-06 Alderbio Holdings Llc Anti-NGF compositions and use thereof
US20140302027A1 (en) * 2011-09-26 2014-10-09 University Of Louisville Research Foundation, Inc. Methods of treating periodontal inflammation and periodontal bone loss
US8999927B2 (en) * 2012-04-02 2015-04-07 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Glial cell line-derived neurotrophic factor (GDNF) compositions and use thereof
EP3538560A4 (en) 2016-11-10 2020-06-17 Keros Therapeutics, Inc. GDNF FUSION POLYPEPTIDES AND METHODS OF USE
EP3628315A1 (en) 2018-09-28 2020-04-01 Université de Caen Normandie Combination of acetylcholinesterase inhibitor and 5-ht4 receptor agonist as neuroprotective agent in the treatment of neurodegenerative diseases

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4518584A (en) * 1983-04-15 1985-05-21 Cetus Corporation Human recombinant interleukin-2 muteins
DE3572982D1 (en) * 1984-03-06 1989-10-19 Takeda Chemical Industries Ltd Chemically modified lymphokine and production thereof
US4892538A (en) * 1987-11-17 1990-01-09 Brown University Research Foundation In vivo delivery of neurotransmitters by implanted, encapsulated cells
US5158881A (en) * 1987-11-17 1992-10-27 Brown University Research Foundation Method and system for encapsulating cells in a tubular extrudate in separate cell compartments
US5106627A (en) * 1987-11-17 1992-04-21 Brown University Research Foundation Neurological therapy devices
US5011472A (en) * 1988-09-06 1991-04-30 Brown University Research Foundation Implantable delivery system for biological factors
WO1990006952A1 (en) * 1988-12-22 1990-06-28 Kirin-Amgen, Inc. Chemically modified granulocyte colony stimulating factor
US5229500A (en) * 1989-08-30 1993-07-20 Regeneron Pharmaceuticals, Inc. Brain derived neurotrophic factor
ATE403713T1 (de) * 1989-10-16 2008-08-15 Amgen Inc Stamzellfaktor
WO1991010470A1 (en) * 1990-01-08 1991-07-25 Brown University Research Foundation Devices and methods for enhanced delivery of active factors
US5202428A (en) * 1990-06-20 1993-04-13 The Salk Institute For Biological Studies DNA encoding neurotropic growth factor
US5252714A (en) * 1990-11-28 1993-10-12 The University Of Alabama In Huntsville Preparation and use of polyethylene glycol propionaldehyde
JP3385040B2 (ja) * 1991-02-14 2003-03-10 武田薬品工業株式会社 グリア活性化因子およびその製造法
DE69233407T2 (de) * 1991-09-20 2005-09-08 Amgen Inc., Thousand Oaks Glial neurotrophe faktor
AU3129793A (en) * 1991-11-08 1993-06-07 General Hospital Corporation, The Methods for the treatment of neuronal damage associated with ischemia, hypoxia or neurodegeneration
ATE218893T1 (de) * 1993-08-12 2002-06-15 Neurotech Sa Biokompatible immunoisolatorische kapseln, die genetisch veränderte zellen enthalten
WO1995017203A1 (en) * 1993-12-22 1995-06-29 The University Of Medicine And Dentistry Of New Jersey Novel nucleic acid sequences isolated from glial cells
FR2717824B1 (fr) * 1994-03-25 1996-04-26 Rhone Poulenc Rorer Sa Virus recombinants, préparation et utilisation en thérapie génique.
US5641750A (en) * 1995-11-29 1997-06-24 Amgen Inc. Methods for treating photoreceptors using glial cell line-derived neurotrophic factor (GDNF) protein product
US5641749A (en) * 1995-11-29 1997-06-24 Amgen Inc. Method for treating retinal ganglion cell injury using glial cell line-derived neurothrophic factor (GDNF) protein product

Also Published As

Publication number Publication date
DE69634301T2 (de) 2005-06-09
DK0852585T3 (da) 2005-05-09
NZ319040A (en) 2001-02-23
JP4761409B2 (ja) 2011-08-31
EP0852585A1 (en) 1998-07-15
US5731284A (en) 1998-03-24
JPH11514860A (ja) 1999-12-21
AU711053B2 (en) 1999-10-07
AU7117596A (en) 1997-04-17
WO1997011965A1 (en) 1997-04-03
DE69634301D1 (de) 2005-03-10
CA2232789A1 (en) 1997-04-03
ES2237775T3 (es) 2005-08-01
SI0852585T1 (en) 2005-06-30
CA2232789C (en) 2001-02-27
ATE288447T1 (de) 2005-02-15
EP0852585B1 (en) 2005-02-02

Similar Documents

Publication Publication Date Title
PT852585E (pt) Metodo de tratamento da doenca de alzheimer utilizando um produto proteico de factor neurotrofico derivado de uma linha de celulas gliais.
GR3034194T3 (en) Method for treating retinal ganglion cell injury using glial cell line-derived neurotrophic factor (gdnf) protein product
Rothbard et al. Differences in the carbohydrate structures of neural cell-adhesion molecules from adult and embryonic chicken brains.
IL121790A0 (en) Method for preventing and treating sensorineural hearing loss and vestibular disorders using glial cell line-derived neurotrophic factor (GDNF) protein product
EP0414275A3 (en) Process for the preparation of cyclic aminoacid derivitives as well as the intermediate products
EA199900464A1 (ru) Способы и композиции для стимуляции роста невритов
DE3686927D1 (de) Neovaskularisierungsinhibitoren und deren herstellung.
DE69913665D1 (de) Verwendung von follistatin zur herstellung eines arzneimittels zur behandlung von muskuläre krankheiten
SE8104482L (sv) Forfarande for framstellning av ett faktor viii (ahf)-hogkoncentrat
DK0562508T3 (da) Nyt knogle-relateret protein OSF-2, fremgangsmåde til dets fremstilling samt farmaceutisk præparat med indhold deraf
NO175594C (no) Fremgangsmåte for isolering av heparin-bindende hjerne-mitogen
ATE151774T1 (de) Cyclopentanperhydrophenanthren-17-beta-(3-furyl - 3-derivate und pharmazeutische präparate davon, zur behandlung von kardiovaskulär-erkrankungen
ATE218856T1 (de) Aminotetralinderivat zur behandlung von herzkreislauferkrankung
EP1736468A3 (en) Isatin derivatives with neurotrophic activity useful in the treatment of diseases mediated by the nerve growth factor (NGF) activation
BR9915803A (pt) Composição para o tratamento de neuropatia da retina ou cabeça de nervo ótico, e, processo para tratamento de neuropatia da retina ou cabeça de nervo ótico
CA2008107A1 (en) 3- or 4-substituted oxotremorine derivatives
ATE163424T1 (de) Neue 17-(3-imino-2-alkyl-propenyl)-5beta-14beta- androstanderivate, zur behandlung von kardiovaskulären erkrankungen, ein verfahren zu ihrer herstellung und pharmazeutische präparate davon
JPH05125097A (ja) 神経細胞およびグリア細胞に作用する新規タンパクおよびそれを含有する医薬品
IT1265305B1 (it) Derivati metallorganici degli acidi s-acil-2-(s)-(2-pirrolidon-5-(s)- carbonilamido)-3-mercapto propionici con selenio, procedimento per la
GR900100691A (el) Νευροτροφικός παράγοντας ακτινωτού.